Drug Index


Mechanism :

The mode of action of sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties and to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls.

Indication :

  • Inflammatory bowel disease
  • Juvenile idiopathic arthritis

Contraindications :

Hypersensitivity to sulfasalazine, its metabolites, sulfonamides or salicylate in patients with intestinal or urinary obstruction and in patients with porphyria, as the sulfonamides have been reported to precipitate an acute attack. Contraindicated in children <2 years of age and caution in patients with G6PD deficiency.

Dosing :

<2 years:
Safety and efficacy not established.
≥2 years:
Acute Attack or relapse: 40-60 mg/kg/day PO in divided doses, Maintenance Dosage: 20-30 mg/kg/day PO in divided doses.

Adverse Effect :

Cyanosis, hemolytic anemia, stomatitis, elevated hepatic enzymes, leukopenia, thrombocytopenia, hypoglycemia, goitre, nausea, anorexia, vomiting, oligospermia, headache, dyspepsia, rash, abdominal pain, fever, pruritus, dizziness, urticaria, exacerbation of colitis

Interaction :

Digoxin and Folic Acid: May reduce gastrointestinal absorption.
Antibiotics: That alter intestinal flora may interfere with conversion of sulfasalazine to sulfapyridine and 5-aminosalicylic acid (5-ASA) decreasing its effectiveness.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function. Use with caution
10-20Dose as in normal renal function. Use with caution
<10Start at very low dose and monitor. Use with caution

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnlikely to be dialysed. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

Dose adjustment guidelines are not available. In the setting of impaired liver function, extreme caution should be taken when using this drug. Discontinue drug as soon as signs of liver toxicity or jaundice develops. Hepatic necrosis can occur. Slow acetylators are at an increased incidence of adverse effects, perhaps due to increased sulfapyridine concentrations.
10/27/2020 00:25:56 Sulfasalazine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0